Selen Gozde Kaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Selen Gozde Kaya has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Gokcen Eren
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, 06330 Ankara, Türkiye
3 shared publications - Mahmut Gozelle
Gazi Üniversitesi
3 shared publications - Yesim Ozkan
Department of Biochemistry, Faculty of Pharmacy Gazi University Ankara Türkiye
3 shared publications - Alberto Massarotti
Dipartimento di Scienze del Farmaco Università degli Studi del Piemonte Orientale Novara Italy
2 shared publications - Erva Ozkan
Department of Biochemistry, Faculty of Pharmacy Ankara Medipol University Ankara Türkiye
2 shared publications - Filiz Bakar-Ates
Department of Biochemistry, Faculty of Pharmacy, Ankara University, 06560 Ankara, Turkey
2 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (2) , e70256
Structure‐Guided Optimization and Biological Validation of 1,3,4‐Thiadiazole‐Based SIRT2 Inhibitors Reinforcing Channel Entrance Interactions
SIRT2, the cytoplasmic member of the sirtuin family, is generally acknowledged to promote cancer and contribute to the progression of various pathologies, including neurodegeneration, inflammation, obesity, and bacterial infection through the deacetylation of target substrates. In our previous efforts we identified potent and highly selective SIRT2 inhibitors with IC 50 values in the micromolar range. To further optimize their activity, we performed molecular docking‐guided design and subsequent synthesis of a series of novel 1,3,4‐thiadiazole derivatives. SIRT inhibitory screening identified that ST131 and ST132 achieved moderate inhibitory effects against SIRT2 with IC 50 values of 8.95 and 6.62 µM, respectively. Moreover, cellular assays in MCF‐7 breast cancer cells revealed that ST132 has shown an antiproliferative effect, as well as increased acetylated α‐tubulin expression levels, which is typically consistent with SIRT2 inhibition. In addition, docking studies were performed to analyze and rationalize the structural differences responsible for SIRT2 activity, shedding light on the importance of the interactions occurring at the entrance of the binding site. Finally, molecular mechanics‐generalized born surface area (MM‐GBSA) and molecular dynamics (MD) simulation approaches were conducted to verify the stability of ST132 in the complex with SIRT2.
- 10 March 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (2) , e70256
Open AccessStructure‐Guided Optimization and Biological Validation of 1,3,4‐Thiadiazole‐Based SIRT2 Inhibitors Reinforcing Channel Entrance Interactions
SIRT2, the cytoplasmic member of the sirtuin family, is generally acknowledged to promote cancer and contribute to the progression of various pathologies, including neurodegeneration, inflammation, obesity, and bacterial infection through the deacetylation of target substrates. In our previous efforts we identified potent and highly selective SIRT2 inhibitors with IC 50 values in the micromolar range. To further optimize their activity, we performed molecular docking‐guided design and subsequent synthesis of a series of novel 1,3,4‐thiadiazole derivatives. SIRT inhibitory screening identified that ST131 and ST132 achieved moderate inhibitory effects against SIRT2 with IC 50 values of 8.95 and 6.62 µM, respectively. Moreover, cellular assays in MCF‐7 breast cancer cells revealed that ST132 has shown an antiproliferative effect, as well as increased acetylated α‐tubulin expression levels, which is typically consistent with SIRT2 inhibition. In addition, docking studies were performed to analyze and rationalize the structural differences responsible for SIRT2 activity, shedding light on the importance of the interactions occurring at the entrance of the binding site. Finally, molecular mechanics‐generalized born surface area (MM‐GBSA) and molecular dynamics (MD) simulation approaches were conducted to verify the stability of ST132 in the complex with SIRT2.
- Open Access
- 12 June 2024
- Published by Wiley in Drug Development Research
- Vol. 85 (4) , e22224
2‐(Methyl(phenyl)amino)‐N‐(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition
The mammalian cytoplasmic protein SIRT2, a class III histone deacetylase family member, possesses NAD+‐dependent lysine deacetylase/deacylase activity. Dysregulation of SIRT2 has been implicated in the pathogenesis of several diseases, including neurological and metabolic disorders and cancer; thus, SIRT2 emerges as a potential therapeutic target. Herein, we identified a series of diaryl acetamides (ST61‐ST90) by the structural optimization of our hit STH2, followed by enhanced SIRT2 inhibitory potency and selectivity. Among them, ST72, ST85, and ST88 selectively inhibited SIRT2 with IC50 values of 9.97, 5.74, and 8.92 μM, respectively. Finally, the entire study was accompanied by in silico prediction of binding modes of docked compounds and the stability of SIRT2‐ligand complexes. We hope our findings will provide substantial information for designing selective inhibitors of SIRT2.
- 12 June 2024
- Published by Wiley in Drug Development Research
- Vol. 85 (4) , e22224
Open Access2‐(Methyl(phenyl)amino)‐N‐(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition
The mammalian cytoplasmic protein SIRT2, a class III histone deacetylase family member, possesses NAD+‐dependent lysine deacetylase/deacylase activity. Dysregulation of SIRT2 has been implicated in the pathogenesis of several diseases, including neurological and metabolic disorders and cancer; thus, SIRT2 emerges as a potential therapeutic target. Herein, we identified a series of diaryl acetamides (ST61‐ST90) by the structural optimization of our hit STH2, followed by enhanced SIRT2 inhibitory potency and selectivity. Among them, ST72, ST85, and ST88 selectively inhibited SIRT2 with IC50 values of 9.97, 5.74, and 8.92 μM, respectively. Finally, the entire study was accompanied by in silico prediction of binding modes of docked compounds and the stability of SIRT2‐ligand complexes. We hope our findings will provide substantial information for designing selective inhibitors of SIRT2.
- 1 June 2019
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 89, 60-73
Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors
- 1 June 2019
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 89, 60-73
Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors